GeoVax Labs (GOVX) vs Lisata Therapeutics (LSTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
GeoVax Labs is the larger company by market cap ($985,459 vs $647,451), about 1.5 times the size. GeoVax Labs converts more of its revenue into profit, with a net margin of -862.3% versus -9756.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GOVX | LSTA |
|---|---|---|
| Share price | $1.81 | $0.8989 |
| Market cap | $985.46K | $647.45K |
| 1-day change | -5.24% | -1.22% |
| YTD return | — | -51.67% |
| 1-year return | — | -54.14% |
| 5-year return | — | -93.89% |
| EPS (TTM) | $-15.03 | $-28.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.49M | $170.00K |
| Revenue growth (YoY) | -37.06% | -83.00% |
| Net income (latest FY) | $-21.46M | $-16.59M |
| Operating margin | -869.34% | -10711.18% |
| Net margin | -862.34% | -9756.47% |
| 52-week high | $270.60 | $76.05 |
| 52-week low | $1.51 | $0.85 |
| Distance from 52-week high | -99.33% | -98.82% |
| Analyst consensus | none | none |
| Avg. price target upside | +452.49% | — |
| Average volume | 213.41K | 13.46K |
| Shares outstanding | 544.45K | 720.27K |
| Employees | 19 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GeoVax Labs is more profitable, keeping -862.3 cents of every revenue dollar as net income versus -9756.5 cents for Lisata Therapeutics.
- GeoVax Labs grew revenue faster in its latest fiscal year (-37.06% vs -83.00%).
About GeoVax Labs
GOVX stock →GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Lisata Therapeutics
LSTA stock →Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
GOVX vs LSTA FAQ
Which is bigger, GeoVax Labs or Lisata Therapeutics?
GeoVax Labs (GOVX) is larger, with a market capitalization of $985.46K compared with $647.45K for Lisata Therapeutics (LSTA).
Are GeoVax Labs and Lisata Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.